Changing outcome in inflammatory neuropathies

Draak, Thomas H P; Vanhoutte, Els K.; Nes, Sonja I. van; Gorson, Kenneth C.; Pol, W. Ludo van der; Notermans, Nicolette C.; Nobile‐Orazio, Eduardo; Léger, J.-M.; Bergh, Peter Van den; Lauria, Giuseppe; Bril, Vera; Katzberg, Hans D.; Lunn, Michael P.; Pouget, Jean; Kooi, Anneke J. van der; Hahn, Angelika F.; Doorn, Pieter A. van; Cornblath, David R.; Berg, Leonard H. van den; Faber, Catharina G.; Merkies, Ingemar S.J.

doi:10.1212/wnl.0000000000001044

Cited by 95 publications

(120 citation statements)

References 40 publications

Supporting

Mentioning

114

Contrasting

Unclassified

Order By: Relevance

“…54 The utility of home evaluation of I-RODS has been previously discussed. 16 A small study found strong correlations between clinic and home evaluations of I-RODS and INCAT scores in leg function, although INCAT scores for arm function showed significant differences, with home evaluations typically scoring 1 point less. 55 In some clinical practices, frequent patient-reported grip strength collection at home with electronic communication to the physician is utilized to complement outcomes collected during routine clinical visits.…”

Section: Practical Application Of Outcome Measuresmentioning

confidence: 98%

“…16 The I-RODS offers a more sensitive outcome measure than INCAT-ODDS or OLNS, and it has been proposed as the primary measure of disability in future clinical trials involving patients with GBS and CIDP. 17 Feasibility is both an advantage and potential limitation of the I-RODS.…”

Section: The Rasch-built Overall Disability Scalementioning

confidence: 99%

“…16 Another potential disadvantage is the observation that in different geographical regions, item bias was observed in 6 of the 24 (25%) items, which suggests that the scale requires further cross-cultural exploration. 17 …”

Section: The Rasch-built Overall Disability Scalementioning

confidence: 99%

See 2 more Smart Citations

Optimizing the Use of Outcome Measures in Chronic Inflammatory Demyelinating Polyneuropathy

Allen¹,

Gelinas

Lewis

et al. 2017

US Neurology

View full text Add to dashboard Cite

The challenges encountered during the assessment of patients with chronic inflammatory demyelinating polyneuropathy (CIDP) are many. Ideally, CIDP outcome measures capture impairments in disability, strength, and sensory dysfunction, and quality of life (QoL). A number of outcome measures have been validated for this purpose. Disability outcomes include the adjusted inflammatory neuropathy cause and treatment (INCAT) disability score, INCAT overall disability sum score (ODSS), and overall neuropathy limitations scale (ONLS). A more sensitive disability score, the inflammatory Rasch-built overall disability scale (I-RODS), has also been validated for use in clinical trials and may better capture clinically meaningful changes in those with CIDP. Strength and sensory impairment can be assessed in a number of ways, including the INCAT sensory subscore (ISS), Medical Research Council sum score, and Martin vigorimeter or Jamar dynamometer grip strength. However, the feasibility of applying and interpreting these measures during routine daily practice has been questioned. Furthermore, these outcome measures may not reflect other factors that can impair QoL in those affected by CIDP, such as pain and fatigue. A valid, reliable, and responsive composite measure that addresses all aspects of impairment faced by patients with CIDP remains an unmet need in clinical practice.

show abstract

Section: Practical Application Of Outcome Measuresmentioning

confidence: 98%

Section: The Rasch-built Overall Disability Scalementioning

confidence: 99%

See 1 more Smart Citation

Optimizing the Use of Outcome Measures in Chronic Inflammatory Demyelinating Polyneuropathy

Allen¹,

Gelinas

Lewis

et al. 2017

US Neurology

View full text Add to dashboard Cite

show abstract

“…It pointed out a better evaluation of data analysis with the Rasch method, which enables a transformation of ordinal data into interval metric data, increasing the level of precision in the assessment. The Inflammatory Rasch-built Overall Disability scale offers the promise of being a more sensitive measure and is highly recommended in future trials involving patients with GBS and CIDP [101].…”

Section: Improvement In Assessment Of Dysimmune Neuropathies For Clinmentioning

confidence: 99%

Immunotherapy in Peripheral Neuropathies

Léger¹,

Guimarães‐Costa²,

Muntean³

2016

Neurotherapeutics

View full text Add to dashboard Cite

Immunotherapy has been investigated in a small subset of peripheral neuropathies, including an acute one, Guillain-Barré syndrome, and 3 chronic forms: chronic inflammatory demyelinating polyradiculoneuropathy, multifocal motor neuropathy, and neuropathy associated with IgM anti-myelin-associated glycoprotein. Several experimental studies and clinical data are strongly suggestive of an immune-mediated pathogenesis. Either cell-mediated mechanisms or antibody responses to Schwann cell, compact myelin, or nodal antigens are considered to act together in an aberrant immune response to cause damage to peripheral nerves. Immunomodulatory treatments used in these neuropathies aim to act at various steps of this pathogenic process. However, there are many phenotypic variants and, consequently, there is a significant difference in the response to immunotherapy between these neuropathies, as well as a need to improve our knowledge and long-term management of chronic forms.

show abstract

“…First, the concept of MCID was applied to two outcome measures that are based on ordinal scales and are considered non-linear (INCAT and MRC) (Vanhoutte et al, 2013;Draak et al, 2014); therefore, the calculated MCID cut-off values may vary across the range of values for these scales (Merkies et al, 2010;Vanhoutte et al, 2013). Such variations in MCID have been demonstrated in several articles based on the varying measurement imprecisions (standard errors) (Heesch et al, 2006;Hobart and Cano, 2009;Vanhoutte et al, 2013).…”

mentioning

confidence: 99%